Eckert & Ziegler AG, a specialist for isotope-based applications in medicine, science and industry, is expanding its cooperation program with promising drug developers in the field of nuclear medicine and will support Curasight, a spin-off based on research by the group of Professor Andreas Kjaer at the National University Hospital (Rigshospitalet) and University of Copenhagen, in obtaining…
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer, is reported in the research journal Nature Methods.
Researchers in Canada and the U.K. have for the first time sequenced and assembled de novo the full genome of a living organism, the bacteria Escherichia Coli, using Oxford Nanopore's MinIONTM device, a genome sequencer that can fit in the palm of your hand.
Nowadays the concept of personalised medicine is usually applied to oncology. However, there are other clinical disciplines in which therapies tailored to the individual patient are within reach, viz. ophthalmology. In the researchers’ limelight is intravitreal drug delivery since the outcomes of injections into the vitreous differ from patient to patient. Ophthalmologists in Vienna, Austria,…
Given the increasing focus on telehealth and telecare services aimed at improving long-term patients’ living conditions and save costs, numerous pilots in various countries have been conducted for proof of concept purposes. Among these, the United Kingdom’s ‘Whole System Demonstrator’ (WSD) programme is the largest randomised controlled trial. Set up by the English National Health Service…
No alcohol, but exercise and a healthy diet – that’s what women can do to help prevent breast cancer recommends Prof. Thomas Helbich (Director of Molecular and Gender Imaging at the Medical University of Vienna) who hosted the European Institute for Biomedical Imaging Research (EIBIR) session ‘The complexity of personalized breast care’ at ECR 2015. Report: Chrissanthi Nikolakudi
Early diagnosis and effective therapy of periprosthetic joint infections (PJI) remain a challenge for many physicians due to the complexity and heterogeneity of clinical symptoms. As individual solutions are needed, opportunities to discuss and exchange ideas are welcome, as clearly shown during the satellite symposium on the diagnosis and treatment of periprosthetic knee infections held at this…
At the close of the Gastrointestinal Medicine and Surgery meeting in Leipzig, Professor Peter R Galle, Congress President of the German Society for Gastroenterology, Digestive and Metabolic Diseases, spoke with EH about today’s emphasis on interdisciplinary exchange and the need to augment cooperation even further. Report: Chrissanthi Nikolakudi
Among updates on breast cancer diagnostics and treatments aired at the 33rd German Society for Senology meeting last year was SpheroTest, an evidence-based tool that helps select the most effective drug for each individual cancer patient. Report: Anja Behringer
Personalised medicine is often equated with the development of drugs tailored to the genetic make-up of patients or cancers.
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years
Over the next few years, the University Medical Center (UMC) Utrecht and Quirem Medical will be working closely together to maximize the benefits of using holmium microspheres to treat liver cancer patients worldwide.
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor’s blood supply – is working.
Two things that radiologists resist – structured reporting and (computer-assisted) quantification – are the very things that Gabriel Krestin believes are essential to advance diagnosis in the brave new world of omic-medicine that is emerging.
Healthcare is undergoing a major change set to offer a real prospect of far more genetically targeted treatments, according a leading human geneticist Sir John Burn, Professor of Clinical Genetics at Newcastle University, England.
In the country’s first scientific study to correlate the demographic changes and frequency of tumorous diseases, demographic changes have led scientists to forecast a significant increase in the number of cancerous diseases in coming years.
Radiologists, EU policy makers and medical industry in drive to strengthen collaboration on personalised medicine
In 1839 Richard Thoma was the first to observe that arteries respond to flow: he identified a fundamental relationship between blood flow and arterial calibre.
Like any other cancer – breast cancer is a highly individual disease, shaped by many factors such as age, health status or genetics. Due to the complex web of molecular pathological processes and resistance mechanisms it is very difficult to select the most effective therapy for each patient.
About 20 years ago the first tumour boards were set up in Germany. Initiated and led by surgeons, they not only invited oncologists, radiotherapists and radiologists to conferences but also, increasingly often, pathologists.
With the effectiveness of ‘tumour board review’ in the USA questioned in a 2012 study published in the Journal of the National Cancer Institute, Mark Nicholls sought the opinion of UK-based consultant urological surgeon Ben Challacombe
ESR President Gabriel Krestin introduced a major theme for the society's congress with personalized radiology. "There is nothing more personal in healthcare than a medical image," he told fellow radiologists.
In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.
‘We aim to develop an understanding of which novel research activities could bring benefits for patients,’ explained Professor Christof von Kalle, Director of the Department of Translational Oncology, NCT (German National Centre for Tumour Diseases) and the German Cancer Research Centre (DKFZ), speaking on translational activities during the New Cancer Targets gathering in Heidelberg this…
A dynamic new consortium was launched in October during the recent Innovation in Oncology event organised by the German Cancer Research Centre (DKFZ) with Heidelberg University Hospital.